Q2 2024 Johnson & Johnson Earnings Call Transcript
Key Points
- Johnson & Johnson (JNJ) reported worldwide sales of $22.4 billion for Q2 2024, a 6.6% increase year-over-year.
- Innovative medicine sales grew by 7.8%, driven by key brands and new product launches, with 10 assets delivering double-digit growth.
- MedTech sales increased by 4.4%, supported by new product introductions and strong procedure volumes.
- The company achieved significant clinical and regulatory milestones, including FDA approval for CARVYKTI in earlier lines of therapy.
- Johnson & Johnson (JNJ) increased its full-year 2024 operational sales guidance by $500 million, reflecting the completion of the Shockwave acquisition.
- Net earnings for the quarter were $4.7 billion, with diluted earnings per share decreasing to $1.93 from $2.05 a year ago.
- MedTech growth fell below expectations, with a revised growth forecast closer to 6% for 2024, down from the upper range of 5% to 7%.
- Cost of product sold margin deleveraged by 60 basis points due to product mix and macroeconomic factors.
- The effective tax rate increased to 18.5% from 14.7% in the same period last year, driven by unfavorable one-time international audit settlements.
- The company faces competitive pressures in several areas, including neuroscience and MedTech, impacting overall performance.
Good morning and welcome to Johnson & Johnson's second quarter 2024 earnings conference call. (Operator Instructions) This call is being recorded. (Operator Instructions) I would now like to turn the conference over to Johnson & Johnson. Please go ahead.
Hello, everyone. This is Jessica Moore, Vice President of Investor Relations for Johnson & Johnson. Welcome to our company's review of the second quarter business results and our full year financial outlook for 2024.
A few logistics before we get into the details. As a reminder, you can find additional materials, including today's presentation and associated schedules on the Investor Relations section of the Johnson & Johnson website at investor.jnj.com.
Please note that this presentation contains forward-looking statements regarding, among other things, the company's future operating and financial performance, market position, and business strategy. You are cautioned not to rely on these forward
| Access to All Earning Calls and Stock Analysis | |
| 30-Year Financial on one screen | |
| All-in-one Stock Screener with unlimited filters | |
| Customizable Stock Dashboard | |
| Real Time Insider Trading Transactions | |
| 8,000+ Institutional investors’ 13F holdings | |
| Powerful Excel Add-in and Google sheets Add-on | |
| All data downloadable | |
| Quick customer support | |
| And much more... |
Trustpilot
We'd love to learn more about your experiences on GuruFocus.com and how we can improve!
Take Survey
